Paper Details

  1. Home
  2. Paper Details

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review.

Author: DulmageBrittany, EvansBrady, GudjonssonJohann E, KaffenbergerBenjamin H, MacklisPaul C, RosenbachMisha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

While cutaneous adverse events of newly approved anti-cancer drugs are well-documented, those related to non-cancer drugs are less studied. This systematic review investigated cutaneous adverse events associated with 180 non-oncologic drugs approved by the US Food and Drug Administration between 2013 and 2018. The review identified 21 drugs with cutaneous adverse events, mostly morbilliform, macular, popular, or maculopapular reactions. Only a few severe reactions were reported, primarily with benznidazole, cannabidiol, and sofosbuvir.
Paper Details　
Original Abstract of the Article :
The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have been for non-cancer drugs and indications. This represents mu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419407/

データ提供：米国国立医学図書館（NLM）

Skin Reactions to Non-Cancer Drugs: A Comprehensive Review

The field of dermatology is constantly evolving, with new drugs being introduced to treat a wide range of conditions. This study delves into the potential cutaneous adverse events associated with newly approved non-cancer drugs, a topic often overlooked in dermatologic literature. The authors conducted a systematic review of 180 non-oncologic medications approved by the FDA between 2013 and 2018, identifying a range of cutaneous adverse events, including morbilliform, macular, popular, and maculopapular reactions. The study also highlights a few severe reactions associated with specific medications, emphasizing the importance of vigilant monitoring for potential adverse effects.

Navigating the Landscape of Cutaneous Adverse Events

This research provides valuable insights into the potential cutaneous adverse events associated with non-cancer drugs, serving as a valuable resource for clinicians and patients alike.

Navigating the Landscape of Cutaneous Adverse Events

Imagine a vast desert landscape, with different types of sand representing various medications. Some sand is harmless, while others can cause skin irritation or even severe reactions. This study is like a guidebook for navigating the desert, helping us identify the potentially dangerous sand and avoid unpleasant encounters.

Dr.Camel's Conclusion

This study serves as a vital reminder of the importance of monitoring for potential side effects, especially with new medications. It emphasizes the need for open communication between patients and their healthcare providers to ensure safe and effective treatment.

Date :
  1. Date Completed 2021-02-03
  2. Date Revised 2021-02-03
Further Info :

Pubmed ID

32557274

DOI: Digital Object Identifier

PMC7419407

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.